Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022

被引：0
|
作者：
Oriana Ciani
Michela Meregaglia
Mario Alberto Battaglia
Gianpaolo Brichetto
Antonella Conte
Claudio Gasperini
Valeria Sansone
机构：
[1] SDA Bocconi School of Management,Government, Health & Not
[2] Health Economics & HTA,for
[3] Italian Multiple Sclerosis (AISM) Society,Profit Division, Center for Research On Health and Social Care Management
[4] Associazione Italiana Sclerosi Multipla (AISM) Rehabilitation Center,Department of Human Neurosciences
[5] Sapienza,Department of Neurosciences
[6] University of Rome,undefined
[7] IRCCS Neuromed,undefined
[8] Italian Society of Neurology (SIN),undefined
[9] S. Camillo Forlanini Hospital,undefined
[10] NeMO Clinical Center,undefined
[11] Neurorehabilitation Unit,undefined
[12] University of Milan,undefined
来源：
Neurological Sciences | 2023年 / 44卷
关键词：
Patient-reported outcomes; European Medicines Agency;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2933 / 2937
页数：4
相关论文
共 50 条
  • [1] Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022
    Ciani, Oriana
    Meregaglia, Michela
    Battaglia, Mario Alberto
    Brichetto, Gianpaolo
    Conte, Antonella
    Gasperini, Claudio
    Sansone, Valeria
    NEUROLOGICAL SCIENCES, 2023, 44 (08) : 2933 - 2937
  • [2] Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
    Ciani, Oriana
    Meregaglia, Michela
    De Lorenzo, Francesco
    Perrone, Francesco
    Pinto, Carmine
    JAMA NETWORK OPEN, 2023, 6 (01) : E2251564
  • [3] RATES OF PATIENT-REPORTED OUTCOME CLAIMS FOR ORPHAN DRUGS APPROVED BY THE EUROPEAN MEDICINES AGENCY
    Jaroslawski, S.
    Toumi, M.
    Auquier, P.
    Dussart, C.
    VALUE IN HEALTH, 2018, 21 : S109 - S109
  • [4] PATIENT-REPORTED OUTCOMES IN LABELS AND PACKAGE LEAFLETS OF DRUGS APPROVED BY THE EUROPEAN MEDICINES AGENCY FROM 2007 TO 2017
    Holm, S. P.
    Fuchsberger, M.
    Bowden, G.
    Buisson, S.
    VALUE IN HEALTH, 2017, 20 (09) : A681 - A681
  • [5] A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021)
    Gnanasakthy, Ari
    Levy, Courtney
    Norcross, Lindsey
    Doward, Lynda
    Winnette, Randall
    VALUE IN HEALTH, 2023, 26 (06) : 893 - 901
  • [6] Inclusion of Patient-Reported Outcome Endpoints in the Summary of Product Characteristics for Non-oncology Drugs Approved by the European Medicines Agency (2018-2022)
    Sauchelli, Sarah
    Levy, Courtney
    Gnanasakthy, Ari
    Doward, Lynda
    Fitzgerald, Kristina A.
    QUALITY OF LIFE RESEARCH, 2024, 33 : S215 - S216
  • [7] A review of patient-reported outcomes for European medicines agency regulatory approval of oncologic drugs between 2017 and 2020
    Torre, Carla
    Teixeira, Maria Manuel
    Borges, Fabio Cardoso
    Barao, Paula
    Rocha, Joao
    Sepodes, Bruno
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 149 - 150
  • [8] Patient-Reported Outcome Labeling for Cardiovascular Drugs Approved in the United States: 2011-2017
    Zettler, Marjorie E.
    Lieu, Hsiao
    CIRCULATION, 2018, 138
  • [9] Patient-Reported Outcome Labeling for Malignant Hematology Drugs Approved in the United States: 2011-2017
    Zettler, Marjorie E.
    Basch, Ethan
    Nabhan, Chadi
    BLOOD, 2018, 132
  • [10] Patient-reported outcome measures
    Ribeiro, Bernard
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2007, 100 (09) : 397 - 397
12345